Optipharm.CO.,LTD Logo

Optipharm.CO.,LTD

Develops animal health solutions, biotherapeutics, and xenotransplantation technology.

153710 | KO

Overview

Corporate Details

ISIN(s):
KR7153710009
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 오송생명6로 63, 청주시

Description

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-03 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-31 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.4 KB
2025-06-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-05-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-02 00:00
[기재정정]투자판단관련주요경영사항 (민군겸용 기술개발사업(형질전환돼지 기반 수혈가능 이종적혈구제제 기술개발) 국책과제 …
Korean 23.4 KB
2025-04-11 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-03-24 00:00
정기주주총회결과
Korean 23.2 KB
2025-03-20 00:00
[기재정정]신규시설투자등
Korean 11.4 KB
2025-03-14 00:00
감사보고서제출
Korean 17.7 KB
2025-03-14 00:00
사업보고서 (2024.12)
Korean 1.5 MB
2025-03-07 00:00
주주총회소집결의
Korean 12.6 KB
2025-03-07 00:00
주주총회소집공고
Korean 154.7 KB

Automate Your Workflow. Get a real-time feed of all Optipharm.CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Optipharm.CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Optipharm.CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.